- Company
- Average 300 days required for new drug approval in Korea
- by Eo, Yun-Ho Nov 18, 2019 02:00am
- It is confirmed that an average of 300 days is spent before a new drug is approved in Korea. The Korean Research-based Pharmaceutical Industry Association (KRPIA), in the 'Study on the New Drug License Period in Korea', disclosed that 115 new drug items approved in Korea took an average of about 300 days for the approval and the review p
- Company
- Combination therapy dominates in DPP-4 inhibitor market
- by Chon, Seung-Hyun Nov 17, 2019 05:35pm
- While dipeptidyl peptidase-4 (DPP-4) inhibitor products are currently leading the Korean oral diabetic treatment market, combination drugs reaffirmed its dominance over the DPP-4 market taking up two-thirds of the pie. Even compared with monotherapy prescription volume, MSD’s combination drug with DDP-4 inhibitor and metformin, Janumet outdid o
- Company
- Prosecution combs vaccine companies for alleged collusion
- by Kim, Jin-Gu Nov 16, 2019 06:29am
- The prosecution set out to investigate on a suspicion of pharmaceutical companies colluding together when supplying vaccine to government. According to pharmaceutical industry on Nov. 14, the prosecution combed ten alleged pharmaceutical companies and distributors on Nov. 13. Companies like GC Pharma, Kwangdong Pharmaceutical, Boryung Ph
- Company
- Novatis Korea, 5 Copyright arrangements including Exelon
- by An, Kyung-Jin Nov 16, 2019 06:28am
- Novartis Korea is working copyright control of some central nervous system (CNS) medicines such as Excelon. According to the industry on 14th Novartis Korea is considering selling the copyrights of some of the CNS products sold by the Rx medicine business division. The intention is to clean up less profitable items and focus sales mark
- Company
- XOSPATA , AML Medicine landing soon in Korea
- by Eo, Yun-Ho Nov 15, 2019 06:28am
- It is anticipated that new AML (acute myeloid leukemia) drugs which are lack of the treatment will be approved . According to the related industry on the 15th, Astellas Pharmaceuticals is in the process of approving from MFDS for 'Acute myeloid leukemia (AML) drug named Xospata (Gilteritinib). The drug is already approved in 2018
- Company
- Samsung Bioepis CEO notes 3 reasons why CAR-T struggles
- by Kim, Jin-Gu Nov 14, 2019 09:07am
- Ko Hang-Seung, CEO of Samsung Bioepis Co., picked three reasons CAR-T cell therapy (“CAR-T”) is struggling &8211; price, patient size and productivity. On Nov. 12, CEO Ko shared his opinions about CAR-T and other next generation treatment options during his keynote speech at BIOplus 2019 in COEX, Seoul. “Data was fairly good when
- Company
- Merck Korea vs GM employee feud sees no end
- by An, Kyung-Jin Nov 14, 2019 09:07am
- After licensing out antihypertensive and anti-diabetic treatments, Merck Korea is finally, and completely, shutting down its General Medicine (GM) division. However, an intense conflict with labor union has deepened as more than a half of the employees have not reached an agreement with the company’s management. The company offering e
- Company
- Rolontis®to get ₩11.6 billion upon FDA's approval
- by An, Kyung-Jin Nov 14, 2019 03:25am
- The royalty scale of Rolontis® was first revealed. Hanmi Pharmaceuticals will receive rayalty of nearly &8361; 12 billion upon final FDA approval. After the release, Hanmi Pharmaceuticals will also likely receive a certain percentage of revenue annually, depending on sales. Spectrum Pharmaceuticals, Hanmi Pharmaceutical’s partner, recent
- Company
- Edarbi & Edarbyclor are going without a hitch
- by Eo, Yun-Ho Nov 14, 2019 03:23am
- Dong-A ST and Takeda Pharmaceutical Company Limited have settled down Edarbi and Edarbyclor prescribed in most general hospitals in Korea. According to the related industry, Edarbyclor combined with Azilsartan medoxomil and Chlorthalidone passed pharmacy and therapeutics committee review of over 30 medical institutions including SNUH, S
- Company
- Kisqali joins reimbursement race as Faslodex combination
- by Eo, Yun-Ho Nov 13, 2019 01:11am
- A third CDK4/6 inhibitor in the Korean market, Kisqali now stands next to the first two drugs, Ibrance and Verzenio, as it applies for National Health Insurance (NHI) reimbursement listing. Novartis Korea recently submitted a reimbursement listing application of Kisqali (ribociclib) after its approval by Ministry of Food and Drug Safety
